DUBLIN--(http://www.researchandmarkets.com/research/p64tlf/alzheimers) has announced the addition of Decision Resources, Inc's new report "Alzheimer's Disease (Event Driven)" to their offering.)--Research and Markets (
The Alzheimer's disease (AD) patient population is large and growing rapidly as the global population ages. Despite a large patient pool, treatment options for AD are at present limited to symptomatic therapies with only modest efficacy of limited duration. Disease-modifying therapies that could slow or halt the progression of the disease are a critical need in this market. Three agents with disease-modifying potential are expected to launch during our ten-year forecast period, resulting in a dramatic expansion of the AD therapy market. Uptake of these drugs will be aided by the availability of improved diagnostics, particularly the amyloid-binding agents for use with PET imaging, leading to identification of patients earlier in the disease course.
Key Topics Covered:
What are the key parameters of the Alzheimer's disease market?
What factors are driving the market for Alzheimer's disease therapies?
What factors are constraining the market for AD therapies?
What are the drug development activities of note in Alzheimer's disease?
What do the experts say?
What key challenges and opportunities remain?
1 Etiology and Pathophysiology
2 Epidemiology and Patient Populations
3 Current Therapies and Medical Practice
4 Unmet Needs
5 Emerging Therapies
6 Market Outlook
For more information visit http://www.researchandmarkets.com/research/p64tlf/alzheimers
Source: Decision Resources, Inc